FY2025 Earnings Forecast for IKT Issued By Lifesci Capital

Inhibikase Therapeutics, Inc. (NYSE:IKT) – Investment analysts at Lifesci Capital issued their FY2025 earnings estimates for Inhibikase Therapeutics in a report issued on Monday, February 23rd. Lifesci Capital analyst G. Maini forecasts that the company will post earnings of ($0.57) per share for the year. The consensus estimate for Inhibikase Therapeutics’ current full-year earnings is ($0.97) per share. Lifesci Capital also issued estimates for Inhibikase Therapeutics’ Q4 2025 earnings at ($0.12) EPS.

IKT has been the topic of several other reports. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Inhibikase Therapeutics in a research report on Friday, December 26th. Jefferies Financial Group restated a “buy” rating on shares of Inhibikase Therapeutics in a research report on Monday, December 29th. Cantor Fitzgerald began coverage on Inhibikase Therapeutics in a report on Thursday, December 11th. They issued an “overweight” rating and a $4.00 target price for the company. Finally, Bank of America started coverage on Inhibikase Therapeutics in a research report on Wednesday, January 21st. They set a “buy” rating and a $6.00 target price on the stock. Four investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $6.00.

Inhibikase Therapeutics Stock Down 2.3%

Shares of NYSE:IKT opened at $2.09 on Thursday. Inhibikase Therapeutics has a 52 week low of $1.33 and a 52 week high of $2.58. The stock has a market capitalization of $157.12 million, a P/E ratio of -0.78 and a beta of 0.84. The firm has a fifty day simple moving average of $1.75 and a two-hundred day simple moving average of $1.66.

Institutional Trading of Inhibikase Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of IKT. Goldman Sachs Group Inc. boosted its holdings in shares of Inhibikase Therapeutics by 277.7% in the first quarter. Goldman Sachs Group Inc. now owns 166,025 shares of the company’s stock valued at $364,000 after purchasing an additional 122,073 shares during the period. Jane Street Group LLC bought a new stake in Inhibikase Therapeutics during the 1st quarter valued at $255,000. Geode Capital Management LLC lifted its holdings in shares of Inhibikase Therapeutics by 228.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,066,700 shares of the company’s stock worth $2,080,000 after buying an additional 741,940 shares during the period. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Inhibikase Therapeutics during the 2nd quarter worth $34,000. Finally, Intech Investment Management LLC purchased a new position in shares of Inhibikase Therapeutics during the second quarter valued at $61,000. Hedge funds and other institutional investors own 3.81% of the company’s stock.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule kinase inhibitors for rare neurodegenerative diseases. Headquartered in New Haven, Connecticut, the company focuses on advancing therapies for central nervous system disorders with high unmet medical need. Its research platform targets key signaling pathways implicated in neuronal survival and degeneration.

The company’s lead investigational candidate, IKT-148009, is a brain-penetrant inhibitor of PDK1 and ABL kinases.